Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.610
-0.030 (-1.83%)
Nov 21, 2024, 12:39 PM EST - Market open
Chemomab Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CMMB stock have an average target of 7.33, with a low estimate of 4.00 and a high estimate of 11. The average target predicts an increase of 355.28% from the current stock price of 1.61.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CMMB stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $13 → $11 | Buy | Reiterates | $13 → $11 | +583.23% | Nov 15, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +148.45% | May 13, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +272.67% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 8, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +334.78% | Dec 19, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.05
from -2.06
EPS Next Year
-0.04
from -0.05
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.05 | -0.04 | -0.04 | ||
| Avg | -0.05 | -0.04 | -0.04 | ||
| Low | -0.05 | -0.04 | -0.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.